No Data
Easton Biopharmaceuticals Gets Registration Certificate for Dihydroxypropyl Theophylline Injection
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Chengdu Easton Biopharmaceuticals (688513.SH): is currently constructing an AI drug development assistance platform.
On March 3rd, GELONGHUI reported that Chengdu Easton Biopharmaceuticals (688513.SH) stated on the interactive platform that the company has always focused on the application potential of AI large models as efficiency tools, encouraging employees to improve work efficiency through the rational use of AI tools. At the same time, the company is also building an AI-assisted platform for drug development, planning to gradually launch functional modules within the year. The planned functionalities include virtual screening (molecular docking), similarity search, substructure search, molecular generation, patent filtering, and molecular drugability assessment.
Yuandong Biology: Yuandong Biology: 2024 Annual Results Express Announcement
Yuandong Biology: 2024 Annual Results Express Announcement
Chengdu Easton Biopharmaceuticals (688513.SH): Net income in 2024 is 0.237 billion yuan, a year-on-year increase of 4.41%.
On February 27, Glonghui reported that Chengdu Easton Biopharmaceuticals (688513.SH) announced its performance report for the 2024 fiscal year. During the reporting period, the company achieved a total operating revenue of 1,348.3015 million yuan, a year-on-year increase of 20.69%; net income attributable to the parent company's owners was 236.5653 million yuan, a year-on-year increase of 4.41%; and net income attributable to the parent company's owners after deducting non-recurring gains and losses was 174.6648 million yuan, a year-on-year increase of 10.84%. During the reporting period, newly launched formulations consistently contributed to growth, and efforts were intensified to expand the market for Active Pharmaceutical Ingredients, with sales both domestically and internationally.
Some Shareholders Feeling Restless Over Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) P/E Ratio